Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement).

Disease-specific survival according to co-expression of Ang-2 and VEGF-A.

Sigve Andersen (186387)
Tom Donnem (186362)
Khalid Al-Shibli (186396)
Samer Al-Saad (186401)
Helge Stenvold (186390)
Lill-Tove Busund (186409)
Roy M. Bremnes (186405)

February 2013

Disease-specific Kaplan-Meier survival curves according to the co-expression of VEGF-A and Ang-2 ...

Survival by EGFR mutation status.

Vanita Noronha (404661)
Kumar Prabhash (404662)
Abhishek Thavamani (404663)
Anuradha Chougule (404664)
Nilendu Purandare (404665)
Amit Joshi (404666)
Rashmi Sharma (404667)
Saral Desai (404668)
Nirmala Jambekar (404669)
Amit Dutt (56978)
Rita Mulherkar (150973)

April 2013

(A) Progression-free survival (PFS) for the EGFR mutant patients was 10 months (95% CI: 8–...

Kaplan-Meier survival curves for the OSCC patients.

Chih-Hsiung Lai (117103)
Shiang-Fu Huang (117106)
Chun-Ta Liao (117115)
I-How Chen (117112)
Hung-Ming Wang (117121)
Ling-Ling Hsieh (117126)

June 2013

(A) Disease-free survival (DFS) based on the mtDNA somatic mutation status. (B) Overall su...

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutation status for patients with nonsquamous NSCLC in Italy, Spain, Germany, and Australia.

Dae Ho Lee (2466736)
Ming-Sound Tsao (18603)
Karl-Otto Kambartel (5687852)
Hiroshi Isobe (69160)
Ming-Shyan Huang (244444)
Carlos H. Barrios (5687855)
Adnan Khattak (5687858)
Filippo de Marinis (3927107)
Smita Kothari (4901623)
Ashwini Arunachalam (4169704)
Xiting Cao (4169698)
Thomas Burke (3451004)
Amparo Valladares (5687861)
Javier de Castro (257472)

August 2018

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...

EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.

A. J. van der Wekken (4401409)
J. L. Kuiper (4401415)
A. Saber (4401397)
M. M. Terpstra (4401391)
J. Wei (1942594)
T. J. N. Hiltermann (4401403)
E. Thunnissen (4401412)
D. A. M. Heideman (4401394)
W. Timens (3948230)
E. Schuuring (775508)
K. Kok (4401406)
E. F. Smit (4401400)
A. van den Berg (3785371)
H. J. M. Groen (2966823)

August 2017

EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.</p

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutation status for patients with nonsquamous NSCLC in Japan, Korea, Taiwan, and Brazil.

Dae Ho Lee (2466736)
Ming-Sound Tsao (18603)
Karl-Otto Kambartel (5687852)
Hiroshi Isobe (69160)
Ming-Shyan Huang (244444)
Carlos H. Barrios (5687855)
Adnan Khattak (5687858)
Filippo de Marinis (3927107)
Smita Kothari (4901623)
Ashwini Arunachalam (4169704)
Xiting Cao (4169698)
Thomas Burke (3451004)
Amparo Valladares (5687861)
Javier de Castro (257472)

August 2018

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...

Overall survival of RCC patients according the genetic proliferation profile.

Ana L. Teixeira (443973)
Francisca Dias (443976)
Marta Ferreira (729477)
Mónica Gomes (319595)
Juliana I. Santos (443977)
Francisco Lobo (33494)
Joaquina Maurício (388027)
José Carlos Machado (26559)
Rui Medeiros (319600)

April 2015

Overall survival of RCC patients according the genetic proliferation profile.</p

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinical variables associated with progression free survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Kaplan-Meier survival curves for histological NSCLC subtypes.

Gian Kayser (281830)
Agnes Csanadi (281831)
Claudia Otto (281832)
Till Plönes (148681)
Nicola Bittermann (281833)
Justyna Rawluk (281834)
Bernward Passlick (148697)
Martin Werner (281835)

February 2013

NSCLC subtypes were diagnosed by H&E on resection specimens (A) and by combined IHC classificatio...

Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with wild type EGFR after the diagnosis of brain metastasis.

Wei-Yuan Chang (4856686)
Yi-Lin Wu (264289)
Po-Lan Su (4856683)
Szu-Chun Yang (4856689)
Chien-Chung Lin (244489)
Wu-Chou Su (216249)

February 2018

Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with w...

Progression-free survival (PFS) and overall survival (OS) among ALK-positive patients, patients who have EGFR activating mutations and wild type both ALK and EGFR (WT/WT).

Jinghui Wang (620961)
Yiran Cai (2225728)
Yujie Dong (2225722)
Jingying Nong (2225731)
Lijuan Zhou (131287)
Guimei Liu (2225725)
Dan Su (8007)
Xi Li (19208)
Shafei Wu (827873)
Xuejing Chen (1536997)
Na Qin (774536)
Xuan Zeng (417018)
Haiqing Zhang (34503)
Zongde Zhang (422658)
Shucai Zhang (829370)

July 2014

(A) PFS for patients receiving the first-line chemotherapy harboring ALK rearrangements, <...

EGFR (exon 18–21) mutation status among NSCLC patients in India.

Anuradha Chougule (404664)
Kumar Prabhash (404662)
Vanita Noronha (404661)
Amit Joshi (404666)
Abhishek Thavamani (404663)
Pratik Chandrani (466705)
Pawan Upadhyay (466706)
Sagarika Utture (466707)
Saral Desai (404668)
Nirmala Jambhekar (466708)
Amit Dutt (56978)

October 2013

(A) EGFR mutation status across all NSCLC samples is shown. Black segment in the inner cir...

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR mutation.

Dalong Wang (2851229)
Minghui Zhang (298745)
Xuan Gao (130773)
Lijuan Yu (659956)

June 2016

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR...

Kaplan-Meier curves for overall survival in ESCC.

Lin Wang (11986)
Ling Shan (155985)
Shaokai Zhang (603032)
Jianming Ying (155982)
Liyan Xue (149161)
Yanling Yuan (603033)
Yongqiang Xie (603034)
Ning Lu (22589)

July 2014

(A) Overall survival according to PIK3CA mutation status (P = 0.251). (B) Overall survival accord...

Disease-specific survival according to co-expression of Ang-2 and VEGF-A.

Sigve Andersen (186387)
Tom Donnem (186362)
Khalid Al-Shibli (186396)
Samer Al-Saad (186401)
Helge Stenvold (186390)
Lill-Tove Busund (186409)
Roy M. Bremnes (186405)

February 2013

Disease-specific Kaplan-Meier survival curves according to the co-expression of VEGF-A and Ang-2 ...

Survival by EGFR mutation status.

Vanita Noronha (404661)
Kumar Prabhash (404662)
Abhishek Thavamani (404663)
Anuradha Chougule (404664)
Nilendu Purandare (404665)
Amit Joshi (404666)
Rashmi Sharma (404667)
Saral Desai (404668)
Nirmala Jambekar (404669)
Amit Dutt (56978)
Rita Mulherkar (150973)

April 2013

(A) Progression-free survival (PFS) for the EGFR mutant patients was 10 months (95% CI: 8–...

Kaplan-Meier survival curves for the OSCC patients.

Chih-Hsiung Lai (117103)
Shiang-Fu Huang (117106)
Chun-Ta Liao (117115)
I-How Chen (117112)
Hung-Ming Wang (117121)
Ling-Ling Hsieh (117126)

June 2013

(A) Disease-free survival (DFS) based on the mtDNA somatic mutation status. (B) Overall su...

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutation status for patients with nonsquamous NSCLC in Italy, Spain, Germany, and Australia.

Dae Ho Lee (2466736)
Ming-Sound Tsao (18603)
Karl-Otto Kambartel (5687852)
Hiroshi Isobe (69160)
Ming-Shyan Huang (244444)
Carlos H. Barrios (5687855)
Adnan Khattak (5687858)
Filippo de Marinis (3927107)
Smita Kothari (4901623)
Ashwini Arunachalam (4169704)
Xiting Cao (4169698)
Thomas Burke (3451004)
Amparo Valladares (5687861)
Javier de Castro (257472)

August 2018

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...

EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.

A. J. van der Wekken (4401409)
J. L. Kuiper (4401415)
A. Saber (4401397)
M. M. Terpstra (4401391)
J. Wei (1942594)
T. J. N. Hiltermann (4401403)
E. Thunnissen (4401412)
D. A. M. Heideman (4401394)
W. Timens (3948230)
E. Schuuring (775508)
K. Kok (4401406)
E. F. Smit (4401400)
A. van den Berg (3785371)
H. J. M. Groen (2966823)

August 2017

EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.</p

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutation status for patients with nonsquamous NSCLC in Japan, Korea, Taiwan, and Brazil.

Dae Ho Lee (2466736)
Ming-Sound Tsao (18603)
Karl-Otto Kambartel (5687852)
Hiroshi Isobe (69160)
Ming-Shyan Huang (244444)
Carlos H. Barrios (5687855)
Adnan Khattak (5687858)
Filippo de Marinis (3927107)
Smita Kothari (4901623)
Ashwini Arunachalam (4169704)
Xiting Cao (4169698)
Thomas Burke (3451004)
Amparo Valladares (5687861)
Javier de Castro (257472)

August 2018

Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...

Overall survival of RCC patients according the genetic proliferation profile.

Ana L. Teixeira (443973)
Francisca Dias (443976)
Marta Ferreira (729477)
Mónica Gomes (319595)
Juliana I. Santos (443977)
Francisco Lobo (33494)
Joaquina Maurício (388027)
José Carlos Machado (26559)
Rui Medeiros (319600)

April 2015

Overall survival of RCC patients according the genetic proliferation profile.</p

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinical variables associated with progression free survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Kaplan-Meier survival curves for histological NSCLC subtypes.

Gian Kayser (281830)
Agnes Csanadi (281831)
Claudia Otto (281832)
Till Plönes (148681)
Nicola Bittermann (281833)
Justyna Rawluk (281834)
Bernward Passlick (148697)
Martin Werner (281835)

February 2013

NSCLC subtypes were diagnosed by H&E on resection specimens (A) and by combined IHC classificatio...

Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with wild type EGFR after the diagnosis of brain metastasis.

Wei-Yuan Chang (4856686)
Yi-Lin Wu (264289)
Po-Lan Su (4856683)
Szu-Chun Yang (4856689)
Chien-Chung Lin (244489)
Wu-Chou Su (216249)

February 2018

Kaplan-Meier curve for overall survival in patients with mutant EGFR mutation versus those with w...

Progression-free survival (PFS) and overall survival (OS) among ALK-positive patients, patients who have EGFR activating mutations and wild type both ALK and EGFR (WT/WT).

Jinghui Wang (620961)
Yiran Cai (2225728)
Yujie Dong (2225722)
Jingying Nong (2225731)
Lijuan Zhou (131287)
Guimei Liu (2225725)
Dan Su (8007)
Xi Li (19208)
Shafei Wu (827873)
Xuejing Chen (1536997)
Na Qin (774536)
Xuan Zeng (417018)
Haiqing Zhang (34503)
Zongde Zhang (422658)
Shucai Zhang (829370)

July 2014

(A) PFS for patients receiving the first-line chemotherapy harboring ALK rearrangements, <...

EGFR (exon 18–21) mutation status among NSCLC patients in India.

Anuradha Chougule (404664)
Kumar Prabhash (404662)
Vanita Noronha (404661)
Amit Joshi (404666)
Abhishek Thavamani (404663)
Pratik Chandrani (466705)
Pawan Upadhyay (466706)
Sagarika Utture (466707)
Saral Desai (404668)
Nirmala Jambhekar (466708)
Amit Dutt (56978)

October 2013

(A) EGFR mutation status across all NSCLC samples is shown. Black segment in the inner cir...

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR mutation.

Dalong Wang (2851229)
Minghui Zhang (298745)
Xuan Gao (130773)
Lijuan Yu (659956)

June 2016

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR...

Kaplan-Meier curves for overall survival in ESCC.

Lin Wang (11986)
Ling Shan (155985)
Shaokai Zhang (603032)
Jianming Ying (155982)
Liyan Xue (149161)
Yanling Yuan (603033)
Yongqiang Xie (603034)
Ning Lu (22589)

July 2014

(A) Overall survival according to PIK3CA mutation status (P = 0.251). (B) Overall survival accord...

Disease-specific survival according to co-expression of Ang-2 and VEGF-A.

Sigve Andersen (186387)
Tom Donnem (186362)
Khalid Al-Shibli (186396)
Samer Al-Saad (186401)
Helge Stenvold (186390)
Lill-Tove Busund (186409)
Roy M. Bremnes (186405)

February 2013

Disease-specific Kaplan-Meier survival curves according to the co-expression of VEGF-A and Ang-2 ...

Survival by EGFR mutation status.

Vanita Noronha (404661)
Kumar Prabhash (404662)
Abhishek Thavamani (404663)
Anuradha Chougule (404664)
Nilendu Purandare (404665)
Amit Joshi (404666)
Rashmi Sharma (404667)
Saral Desai (404668)
Nirmala Jambekar (404669)
Amit Dutt (56978)
Rita Mulherkar (150973)

April 2013

(A) Progression-free survival (PFS) for the EGFR mutant patients was 10 months (95% CI: 8–...

Kaplan-Meier survival curves for the OSCC patients.

Chih-Hsiung Lai (117103)
Shiang-Fu Huang (117106)
Chun-Ta Liao (117115)
I-How Chen (117112)
Hung-Ming Wang (117121)
Ling-Ling Hsieh (117126)

June 2013

(A) Disease-free survival (DFS) based on the mtDNA somatic mutation status. (B) Overall su...

Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement).

Abstract

Extracted data

Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement).

Abstract

Extracted data

Related items

Related items